IDARUBICINA ACCORD 20mg / 20ml injectible solution medication leaflet

L01DB06 • idarubicin • Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances

Idarubicin is a chemotherapy drug used for the treatment of acute leukemia, including acute myeloid leukemia (AML). It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, thereby preventing cell division.

The medication is administered intravenously, as directed by a doctor. It is important to monitor the patient for adverse effects during treatment.

Side effects may include nausea, vomiting, hair loss, bone marrow suppression, or cardiac toxicity. In rare cases, severe allergic reactions may occur.

Idarubicin is not recommended for patients with severe cardiac insufficiency, severe bone marrow suppression, or hypersensitivity to anthracyclines.